AI-designed universal vaccine shows modest immune response in first human trial

Researchers from University of Cambridge have initiated first human trials of an AI-designed vaccine targeting viruses such as Sars, Mers, and Covid-19. Although early results indicate a "modest" immune response, the team is optimistic that this innovative approach could transform vaccine development, paving the way for more stable solutions in future pandemics.

By BRIC Team · BRIC.TV

Published Jun 5, 2026 · 1 min read · 56 views

AI-designed universal vaccine shows modest immune response in first human trial

Key Takeaways

•The University of Cambridge conducted the first human trials of an AI-designed vaccine, targeting viruses like Sars, Mers, and Covid-19.
•Results from the early-stage trial showed a 'modest' effect on immune responses in participants.
•Jonathan Heeney stated, 'We’ve converted vaccine development from being reactive to being future proof.'
•This AI-driven approach aims to create a 'universal vaccine' to reduce the need for frequent updates.
•The trial marks a significant step towards using technology to enhance public health in combating infectious diseases.

First Human Trials of AI-Designed Vaccine

Researchers at University of Cambridge have tested first vaccine created entirely by artificial intelligence on humans. This vaccine targets several viruses,including those causing major outbreaks like Sars,Mers,and Covid-19.

Results from small,early-stage trial showed some immune response among participants. Impact was limited,researchers still see potential for AI to shake up vaccine development. Jonathan Heeney,Cambridge researcher and study co-author, emphasized change,saying, “We’ve turned vaccine development from being reactive to being proactive.”

“Universal vaccine” idea could mean stronger defenses against future pandemics. Current vaccines,like for influenza and Covid-19, often need updates to tackle changing strains . Aim is this vaccine might cut need for constant adjustments,offering more stable viral protection.

World still battling infectious diseases,this trial is a step toward smarter public health solutions . Researchers keep exploring what their findings mean,looking to a future where vaccines get produced faster and more efficiently...